One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Viatris  logo
Viatris VTRS
$ 20.86 1.86%
report update icon

Quarterly report 2026-Q3
added 11-05-2026

Viatris Financial Ratios 2025-2011 | VTRS

Brief overview of Viatris 's financial ratios

Current figures are compared with the company's own five-year history for 2017–2023.

The current valuation set is P/E 336.17x (median 44.98x), EV/EBITDA 156.5x (median 10.5x), P/S 1.19x (median 0.84x). Multiples are on average 42.4% above their own medians. A substantial share of positive expectations may already be priced in.

Current earnings relative to valuation equal about 0.3% on the 1/P/E measure. This is a valuation reference, not an expected payout.

End-period return metrics are ROE -23.9%, ROA -9.5%, ROCE -18.1%. Current return ratios are negative, materially weakening the fundamental profile.

On PEG (1.63x), valuation is stretched relative to growth and requires strong execution.

The time from paying for inputs to receiving cash fell from 165.5 days to 150.5 days. Cash turnover improved.

Overall assessment

Viatris 's market premium is not yet supported by strong capital returns, raising valuation risk.

Annual Financial Ratios Viatris

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- - 336.2 6.5 -10.5 -13.2 672.9 45.0 33.8 38.8 29.4 21.4 28.0 18.3 16.8

P/S

- - 1.2 0.8 0.7 0.7 1.0 1.4 2.0 1.7 2.6 2.6 2.5 1.7 1.5

EPS

-3 -0.5 0.1 1.7 -1.1 -1.1 - 0.7 - - - - - - -

EV (Enterprise Value)

21.2 B 22.1 B 44.6 B 41.3 B 47 B 46.6 B 30.2 B 36 B 46 B 42.3 B 37.4 B 32.5 B 29.7 B 20.3 B 17.1 B

EBITDA per Share

- - 2.92 3.83 3.7 3.34 5.26 5.76 6.04 5.65 5.07 5.26 4.27 3.98 3.63

EV/EBITDA

156.5 7.6 12.7 8.9 10.5 23.2 8.3 9.9 11.7 11.4 12.9 14.3 15.4 10.3 8.9

PEG

- - -30.72 -0.92 1.63 2.1 -7.06 -0.96 0.88 -0.81 -1.06 0.41 4.79 0.79 0.21

P/B

- - 0.9 0.6 0.6 0.4 1.0 1.3 1.8 1.7 2.5 6.1 5.9 3.5 2.6

P/CF

- - 6.3 4.5 4.4 7.2 8.1 13.8 20.1 14.4 21.9 76.3 22.6 18.2 20.5

ROE %

-23.89 -3.40 0.27 9.86 -6.19 -2.92 0.14 2.90 5.23 4.32 8.68 28.37 21.07 19.10 15.32

ROA %

-9.45 -1.53 0.11 4.16 -2.31 -1.09 0.05 1.08 1.94 1.38 3.81 5.85 4.09 5.37 4.63

ROCE %

-8.85 0.03 1.92 3.73 -0.08 -0.41 2.70 3.04 4.84 4.63 7.51 13.24 9.13 11.36 11.67

Current Ratio

1.7 1.8 1.8 1.7 1.6 1.6 1.2 1.4 1.1 1.5 1.6 1.3 1.5 1.8 1.4

DSO

67.0 68.1 71.8 78.8 78.2 59.4 97.1 92.0 110.7 109.1 104.1 107.3 96.2 83.5 84.9

DIO

154.3 146.6 141.9 140.1 140.1 - - 126.7 130.3 140.5 136.6 143.8 157.1 143.2 142.9

DPO

70.9 75.9 75.2 64.0 52.8 42.6 51.0 55.2 50.0 53.7 77.7 78.9 101.2 73.0 72.0

Operating Cycle

221.4 214.7 213.7 218.9 218.3 - - 218.7 241.0 249.6 240.7 251.1 253.2 226.7 227.9

Cash Conversion Cycle

150.5 138.8 138.5 154.9 165.5 - - 163.5 191.0 195.9 163.0 172.2 152.0 153.6 155.9

All numbers in USD currency

Quarterly Financial Ratios Viatris

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

-0.28 -0.1 0.15 -0.2999999999999998 -0.11 - -2.55 -0.43000000000000005 0.08 -0.27 0.1 -0.63 0.28 0.22 0.19 0.83 0.29 0.26 0.33 -0.22000000000000008 0.26 -0.23 -0.86 - -1689743 -9071 0.04 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA per Share

0.71 0.5 0.44 - 0.66 0.7 -1.94 - 0.67 0.3 0.67 -841 0.86 0.8 0.83 1.35 K 0.97 0.98 1.12 2.94 K 0.85 0.52 0.35 - 16.1 M 9.65 M 1.16 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROE %

-4.32 -2.78 -1.98 -22.62 -23.08 -21.76 -23.40 -3.40 -4.36 -3.25 -0.32 0.19 8.73 8.99 9.30 10.18 4.10 3.72 0.82 -5.98 79.39 167.92 -4.85 - 84.08 90.00 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROA %

-1.71 -1.11 -0.79 -9.17 -9.50 -8.95 -9.66 -1.51 -1.87 -1.40 -0.14 0.07 3.70 3.75 3.82 4.11 1.61 1.44 0.34 -2.17 -3.17 -3.73 -1.76 - -1.48 -0.01 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROCE %

0.05 -0.30 0.42 -8.11 -7.97 -7.95 -9.33 -0.02 -0.65 -0.18 1.33 1.74 2.41 2.67 3.05 3.74 4.03 3.48 2.12 -0.04 3.24 3.64 -0.54 - 3.10 1.18 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Current Ratio

1.6 1.7 1.7 1.6 1.7 1.7 1.7 1.8 1.8 1.8 1.7 1.8 1.8 1.8 1.7 1.7 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.0 1.0 1.6 1.6 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

DSO

76.3 75.5 79.4 79.2 80.7 81.6 89.3 90.0 88.9 86.8 91.6 88.7 85.2 82.9 89.7 84.3 79.3 87.0 91.3 90.7 89.1 90.1 97.2 33.7 119.5 130.0 121.1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

DIO

153.2 155.9 153.2 144.8 160.0 169.6 173.3 156.6 159.8 150.7 154.1 145.4 148.3 144.3 149.9 121.0 136.9 140.1 146.6 131.6 132.0 132.4 143.8 - 275.3 292.8 216.9 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

DPO

66.7 68.9 67.7 63.3 68.3 76.5 83.8 74.5 77.3 80.6 87.4 80.0 80.1 77.4 77.7 54.0 58.4 59.9 59.5 54.1 53.3 54.0 54.5 - 95.8 101.9 91.4 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Cycle

229.5 231.4 232.7 223.9 240.7 251.2 262.6 246.6 248.7 237.4 245.7 234.1 233.5 227.2 239.6 205.3 216.2 227.1 237.8 222.3 221.0 222.5 241.0 33.7 394.8 422.8 330.6 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash Conversion Cycle

162.8 162.5 164.9 160.6 172.4 174.7 178.8 172.1 171.4 156.8 158.3 154.2 153.4 149.8 161.9 151.4 157.9 167.2 178.3 168.1 167.8 168.5 186.5 33.7 299.0 320.9 239.2 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Viatris , allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Drug manufacturers industry

Issuer Price % 24h Market Cap Country
ProPhase Labs ProPhase Labs
PRPH
- - $ 5.07 M usaUSA
Zomedica Corp. Zomedica Corp.
ZOM
- -0.21 % $ 98 M usaUSA
Agile Therapeutics Agile Therapeutics
AGRX
- 10.11 % $ 58.2 M usaUSA
Avadel Pharmaceuticals plc Avadel Pharmaceuticals plc
AVDL
- - $ 2.06 B franceFrance
Pacira BioSciences Pacira BioSciences
PCRX
$ 36.48 0.04 % $ 1.63 B usaUSA
Perrigo Company plc Perrigo Company plc
PRGO
$ 16.83 -0.71 % $ 2.33 B usaUSA
Evoke Pharma Evoke Pharma
EVOK
- - $ 36.6 M usaUSA
Solid Biosciences Solid Biosciences
SLDB
$ 7.19 2.35 % $ 629 M usaUSA
Sundial Growers Sundial Growers
SNDL
$ 1.4 -0.36 % $ 361 M canadaCanada
Tilray Tilray
TLRY
$ 2.66 -6.84 % $ 297 M canadaCanada
Aerie Pharmaceuticals Aerie Pharmaceuticals
AERI
- - $ 754 M usaUSA
Veru Veru
VERU
$ 2.12 -3.2 % $ 31.1 M usaUSA
Alimera Sciences Alimera Sciences
ALIM
- - $ 142 M usaUSA
cbdMD cbdMD
YCBD
$ 0.39 1.86 % $ 1.57 M usaUSA
Adamis Pharmaceuticals Corporation Adamis Pharmaceuticals Corporation
ADMP
- 0.86 % $ 117 M usaUSA
China Pharma Holdings China Pharma Holdings
CPHI
$ 0.55 -2.64 % $ 2.36 M chinaChina
Lannett Company Lannett Company
LCI
- 1.15 % $ 7.11 M usaUSA
Zynerba Pharmaceuticals Zynerba Pharmaceuticals
ZYNE
- - $ 55.5 M usaUSA
Eagle Pharmaceuticals Eagle Pharmaceuticals
EGRX
- -39.89 % $ 27.7 M usaUSA
PetIQ PetIQ
PETQ
- 1.64 % $ 400 M usaUSA
Tricida Tricida
TCDA
- - $ 3.25 M usaUSA
DURECT Corporation DURECT Corporation
DRRX
- - $ 50.1 M usaUSA
Athenex Athenex
ATNX
- -23.39 % $ 1.76 M usaUSA
PLx Pharma PLx Pharma
PLXP
- -27.8 % $ 2.56 M usaUSA
Catalent Catalent
CTLT
- - $ 11.5 B usaUSA
Endo International plc Endo International plc
ENDP
- - $ 28.9 M irlandaIrlanda
OptiNose OptiNose
OPTN
- - $ 1.08 B usaUSA
Radius Health Radius Health
RDUS
- - $ 1.42 B usaUSA
Recro Pharma Recro Pharma
REPH
- -4.76 % $ 65.3 M usaUSA
Canopy Growth Corporation Canopy Growth Corporation
CGC
$ 0.59 -5.37 % $ 176 M canadaCanada
Aurora Cannabis Aurora Cannabis
ACB
$ 5.11 -1.07 % $ 280 M canadaCanada
Harrow Health Harrow Health
HROW
$ 30.4 10.67 % $ 1.12 B usaUSA
Cumberland Pharmaceuticals Cumberland Pharmaceuticals
CPIX
$ 5.39 0.37 % $ 80.1 M usaUSA
Relmada Therapeutics Relmada Therapeutics
RLMD
$ 4.24 2.42 % $ 167 M usaUSA
Emergent BioSolutions Emergent BioSolutions
EBS
$ 6.04 -0.98 % $ 323 M usaUSA
Cronos Group Cronos Group
CRON
$ 3.43 -3.25 % $ 1.32 B canadaCanada
Evolus Evolus
EOLS
$ 6.81 -2.51 % $ 439 M usaUSA
Organogenesis Holdings Organogenesis Holdings
ORGO
$ 0.96 5.83 % $ 122 M usaUSA
Bausch Health Companies Bausch Health Companies
BHC
$ 8.33 -0.83 % $ 3.09 B canadaCanada
OrganiGram Holdings OrganiGram Holdings
OGI
$ 0.85 -2.69 % $ 81 M canadaCanada
Rockwell Medical Rockwell Medical
RMTI
$ 7.35 -2.26 % $ 264 M usaUSA
SCYNEXIS SCYNEXIS
SCYX
$ 3.54 1.14 % $ 177 M usaUSA
HEXO Corp. HEXO Corp.
HEXO
- 2.45 % $ 38.1 M canadaCanada
Calliditas Therapeutics AB (publ) Calliditas Therapeutics AB (publ)
CALT
- -0.1 % $ 2.03 B schwedenSchweden
Sonoma Pharmaceuticals Sonoma Pharmaceuticals
SNOA
$ 1.12 -0.88 % $ 1.89 M usaUSA
TherapeuticsMD TherapeuticsMD
TXMD
$ 1.74 2.96 % $ 20.1 M usaUSA
AcelRx Pharmaceuticals AcelRx Pharmaceuticals
ACRX
- 7.5 % $ 6.35 M usaUSA
Assertio Holdings Assertio Holdings
ASRT
- - $ 150 M usaUSA
Jupiter Wellness Jupiter Wellness
JUPW
- - $ 33.6 M usaUSA